New applications (sections 2.1. to 2.12.) Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft opinion at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.
2.7. New applications 2.7.1. Axalimogene filolisbac - EMEA/H/C/004473 Intended for the treatment of cervical cancerScope: timetable for assessment Action: for adoption